Characterization and Changes of Lymphocyte Subsets in Baricitinib‐Treated Patients With Rheumatoid Arthritis: An Integrated Analysis

OBJECTIVE: Baricitinib is an orally administered inhibitor of JAK1 and JAK2 that has been shown to be effective in treating rheumatoid arthritis (RA). This study was undertaken to analyze changes in lymphocyte cell subsets during baricitinib treatment and to correlate these changes with clinical out...

Descripción completa

Detalles Bibliográficos
Autores principales: Tanaka, Yoshiya, McInnes, Iain B., Taylor, Peter C., Byers, Nicole L., Chen, Lei, de Bono, Stephanie, Issa, Maher, Macias, William L., Rogai, Veronica, Rooney, Terence P., Schlichting, Douglas E., Zuckerman, Steven H., Emery, Paul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Rheumatoid Arthritis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6587754/
https://www.ncbi.nlm.nih.gov/pubmed/30058112
http://dx.doi.org/10.1002/art.40680

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6587754/
https://www.ncbi.nlm.nih.gov/pubmed/30058112
http://dx.doi.org/10.1002/art.40680

Ejemplares similares